Nifty
Sensex
:
:
11844.10
39434.72
187.05 (1.60%)
623.33 (1.61%)

Pharmaceuticals & Drugs

Rating :
71/99

BSE: 530239 | NSE: SUVEN

267.95
8.45 (3.26%)
24-May-2019 | 3:52PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  261.90
  •  270.50
  •  260.80
  •  259.50
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  288584
  •  773.26
  •  337.80
  •  182.70

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 3,406.08
  • 23.56
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 3,412.77
  • 0.56%
  • 3.59

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 60.00%
  • 3.89%
  • 23.37%
  • FII
  • DII
  • Others
  • 0.21%
  • 1.76%
  • 10.77%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 16.15
  • 4.15
  • 7.77

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 29.60
  • 1.23
  • 12.45

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 36.38
  • 1.91
  • 16.55

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 18.44
  • 20.70
  • 19.59

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.37
  • 4.18
  • 3.31

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 12.51
  • 14.10
  • 12.59

Quarterly Results

Standalone Figures in Rs. Crores /

Consolidated
Description
Dec 18
Dec 17
Var%
Sep 18
Sep 17
Var%
Jun 18
Jun 17
Var%
Mar 18
Mar 17
Var%
Net Sales
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
EBITDA
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
EBIDTM
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Other Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Depreciation
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PBT
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PATM
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
EPS
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00

Annual Results

Standalone Figures in Rs. Crores /

Consolidated
Description
TTM
Mar 18
Mar 17
Mar 16
Mar 15
Mar 08
Mar 07
Mar 06
Mar 05
Net Sales
-
625.26
543.53
499.52
520.86
117.28
111.92
88.08
63.62
Net Sales Growth
-
15.04%
8.81%
-4.10%
344.12%
4.79%
27.07%
38.45%
 
Cost Of Goods Sold
-
150.91
147.06
162.64
177.61
44.18
42.04
30.66
19.80
Gross Profit
-
474.35
396.47
336.88
343.25
73.10
69.88
57.42
43.83
GP Margin
-
75.86%
72.94%
67.44%
65.90%
62.33%
62.44%
65.19%
68.89%
Total Expenditure
-
427.07
414.46
398.18
361.40
104.61
95.57
77.29
55.10
Power & Fuel Cost
-
33.56
31.50
29.32
28.04
7.95
6.34
5.77
5.13
% Of Sales
-
5.37%
5.80%
5.87%
5.38%
6.78%
5.66%
6.55%
8.06%
Employee Cost
-
61.27
52.17
35.64
31.75
12.25
9.53
7.37
6.25
% Of Sales
-
9.80%
9.60%
7.13%
6.10%
10.45%
8.52%
8.37%
9.82%
Manufacturing Exp.
-
148.78
153.86
139.49
95.91
29.74
27.89
25.17
16.36
% Of Sales
-
23.79%
28.31%
27.92%
18.41%
25.36%
24.92%
28.58%
25.72%
General & Admin Exp.
-
20.66
19.45
22.48
20.14
8.38
7.53
5.85
5.27
% Of Sales
-
3.30%
3.58%
4.50%
3.87%
7.15%
6.73%
6.64%
8.28%
Selling & Distn. Exp.
-
8.57
7.46
6.73
5.17
2.06
2.15
1.58
2.17
% Of Sales
-
1.37%
1.37%
1.35%
0.99%
1.76%
1.92%
1.79%
3.41%
Miscellaneous Exp.
-
3.31
2.95
1.88
2.77
0.05
0.10
0.88
0.12
% Of Sales
-
0.53%
0.54%
0.38%
0.53%
0.04%
0.09%
1.00%
0.19%
EBITDA
-
198.19
129.07
101.34
159.46
12.67
16.35
10.79
8.52
EBITDA Margin
-
31.70%
23.75%
20.29%
30.61%
10.80%
14.61%
12.25%
13.39%
Other Income
-
23.27
21.09
19.62
8.58
3.18
1.46
0.82
1.54
Interest
-
4.63
5.68
5.88
4.71
5.06
3.03
1.65
0.82
Depreciation
-
21.31
21.41
17.50
11.78
4.44
4.01
3.46
3.23
PBT
-
195.53
123.07
97.58
151.55
6.36
10.76
6.49
6.01
Tax
-
71.84
35.88
25.74
42.80
-1.99
-0.51
0.11
3.61
Tax Rate
-
36.74%
29.15%
26.38%
28.24%
-31.29%
-4.74%
1.69%
60.07%
PAT
-
123.69
87.19
71.85
108.75
8.35
11.26
6.39
2.41
PAT before Minority Interest
-
123.69
87.19
71.85
108.75
8.35
11.26
6.39
2.41
Minority Interest
-
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
-
19.78%
16.04%
14.38%
20.88%
7.12%
10.06%
7.25%
3.79%
PAT Growth
-
41.86%
21.35%
-33.93%
1,202.40%
-25.84%
76.21%
165.15%
 
Unadjusted EPS
-
9.70
6.84
5.61
9.04
0.72
3.91
2.55
0.96

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 08
Mar 07
Mar 06
Mar 05
Shareholder's Funds
767.41
667.00
595.28
559.31
106.39
101.52
90.21
81.18
Share Capital
12.73
12.73
12.73
12.73
11.57
5.76
5.00
5.00
Total Reserves
754.68
654.27
582.56
546.59
94.82
95.76
85.21
76.18
Non-Current Liabilities
29.36
28.21
40.54
86.43
57.06
46.78
30.83
33.03
Secured Loans
0.25
22.65
37.08
55.09
54.62
41.49
23.68
19.81
Unsecured Loans
1.14
3.29
4.56
6.36
0.00
0.00
0.00
0.00
Long Term Provisions
3.69
2.84
2.39
2.27
0.00
0.00
0.00
0.00
Current Liabilities
221.04
208.05
210.62
127.39
35.08
24.95
21.98
21.55
Trade Payables
56.82
37.94
35.60
43.89
20.14
11.87
11.63
11.97
Other Current Liabilities
30.27
46.14
48.18
42.45
0.63
1.06
0.29
0.27
Short Term Borrowings
24.94
30.49
24.16
28.24
0.00
0.00
0.00
0.00
Short Term Provisions
109.01
93.49
102.68
12.81
14.32
12.02
10.07
9.31
Total Liabilities
1,017.81
903.26
846.44
773.13
198.53
173.25
143.02
135.76
Net Block
307.73
305.72
305.35
171.95
109.77
95.62
82.77
74.14
Gross Block
375.68
348.92
325.15
290.52
141.20
120.47
101.64
88.59
Accumulated Depreciation
67.95
43.19
19.80
118.57
31.43
24.86
18.87
14.45
Non Current Assets
351.30
322.10
318.79
291.31
115.72
105.60
89.53
84.55
Capital Work in Progress
24.74
9.72
7.20
107.01
3.66
5.02
2.67
3.31
Non Current Investment
0.07
0.07
0.07
0.00
2.29
4.96
4.09
7.09
Long Term Loans & Adv.
18.55
6.39
6.16
10.89
0.00
0.00
0.00
0.00
Other Non Current Assets
0.20
0.20
0.00
1.46
0.00
0.00
0.00
0.00
Current Assets
666.50
581.16
527.66
476.98
82.79
67.60
53.43
51.14
Current Investments
278.73
300.89
0.05
0.04
0.00
0.00
0.00
0.00
Inventories
139.47
92.51
83.46
81.81
24.40
22.90
22.74
19.31
Sundry Debtors
61.54
45.83
53.56
40.17
35.59
16.14
14.99
18.62
Cash & Bank
20.83
9.17
241.40
279.69
3.04
9.78
1.37
2.57
Other Current Assets
165.95
32.89
40.22
41.22
19.77
18.79
14.33
10.63
Short Term Loans & Adv.
115.32
99.87
108.96
34.06
14.93
14.33
9.70
8.81
Net Current Assets
445.46
373.11
317.04
349.59
47.71
42.65
31.45
29.58
Total Assets
1,017.80
903.26
846.45
773.14
198.53
173.24
143.02
135.78

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 18
Mar 17
Mar 16
Mar 08
Mar 07
Mar 06
Mar 05
Cash From Operating Activity
69.94
109.17
67.50
3.94
16.24
5.51
2.11
PBT
195.53
123.07
97.58
6.36
10.76
6.49
5.79
Adjustment
10.32
12.91
10.98
11.22
6.54
6.56
3.97
Changes in Working Capital
-92.37
7.90
-14.36
-12.96
0.46
-6.52
-6.95
Cash after chg. in Working capital
113.47
143.88
94.20
4.63
17.75
6.54
2.81
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-43.54
-34.71
-26.70
-0.69
-1.51
-1.03
-0.70
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-0.61
-310.64
-38.63
-16.20
-20.46
-9.45
-4.11
Net Fixed Assets
-41.78
-26.29
-187.49
-19.37
-21.18
-13.51
Net Investments
-15.06
-342.87
-14.91
2.67
-0.87
4.00
Others
56.23
58.52
163.77
0.50
1.59
0.06
Cash from Financing Activity
-57.70
-30.39
-68.07
5.52
12.62
2.73
-7.51
Net Cash Inflow / Outflow
11.63
-231.86
-39.20
-6.74
8.40
-1.20
-9.51
Opening Cash & Equivalents
8.69
240.55
279.75
9.78
1.37
2.57
12.09
Closing Cash & Equivalent
20.32
8.69
240.55
3.04
9.78
1.37
2.57

Financial Ratios

Standalone /

Consolidated
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 08
Mar 07
Mar 06
Mar 05
Mar 04
Book Value (Rs.)
60.29
52.40
46.77
43.56
9.19
35.21
9.01
8.11
8.16
ROA
12.88%
9.97%
8.87%
22.38%
4.49%
7.12%
4.58%
1.82%
4.11%
ROE
17.25%
13.81%
12.50%
32.91%
8.04%
11.76%
7.46%
2.96%
6.49%
ROCE
26.12%
18.19%
15.43%
37.93%
7.51%
10.74%
7.59%
6.73%
8.95%
Fixed Asset Turnover
1.73
1.62
1.63
2.42
0.92
1.02
0.95
0.80
0.68
Receivable days
31.34
33.32
34.19
26.51
78.68
50.16
68.08
82.03
76.64
Inventory Days
67.71
58.98
60.29
37.16
71.95
73.54
85.16
87.39
85.28
Payable days
38.57
33.17
35.72
32.74
57.23
45.77
52.98
65.92
70.34
Cash Conversion Cycle
60.48
59.13
58.77
30.93
93.40
77.93
100.27
103.49
91.59
Total Debt/Equity
0.04
0.11
0.14
0.20
0.51
0.41
0.26
0.24
0.25
Interest Cover
43.25
22.65
17.61
33.18
2.26
4.55
4.93
8.30
11.60

News Update:


  • Suven Life Sciences - Quarterly Results
    25th May 2019, 13:45 PM

    Read More
  • Suven Life Sciences completes Phase 2 study of SUVN-502 for moderate Alzheimer’s disease
    23rd May 2019, 15:04 PM

    The company expects to report the top-line data of this study at AAIC on July 17, 2019 at Los Angeles

    Read More
  • Suven Life Sciences completes purchase of assets of Rising Pharmaceuticals
    23rd Apr 2019, 09:05 AM

    The company has completed the purchase of the assets of Rising Pharmaceuticals and Rising's subsidiaries to Shore Suven Pharma, Inc

    Read More
  • Suven Life Science gets nod to enhance investment limits in USA subsidiary
    15th Apr 2019, 16:16 PM

    The Board of directors of the company at its meeting held on April 15, 2019 has approved for the same

    Read More
  • Suven Life Science gets nod from US bankruptcy court to buy assets of Rising Pharmaceuticals
    15th Apr 2019, 10:03 AM

    A stalking horse agreement refers to an initial bid for a bankrupt company’s assets and sets the lower limit in a bankruptcy auction

    Read More
  • Suven Life Sciences secures product patents in four countries
    4th Apr 2019, 09:21 AM

    The granted claims of the patents include the class of selective 5-HT4 and M1 PAM compounds

    Read More
  • Suven secures product patents in four countries
    29th Mar 2019, 10:09 AM

    Patents are valid through 2034

    Read More
  • Suven Life Sciences gets nod to form wholly owned subsidiary in US
    11th Mar 2019, 08:58 AM

    The Board of Directors of the Company at its meeting held on March 09, 2019 has approved the same

    Read More
  • Suven Life Sciences inks agreement to buy assets of Rising Pharmaceuticals
    8th Mar 2019, 09:28 AM

    Shore Suven Pharma, Inc. is a joint venture between Suven Life Sciences and Shore Pharma Investments, LLC of USA

    Read More
  • Suven Life Science planning for investments in new overseas subsidiary
    5th Mar 2019, 11:18 AM

    The meeting of Board of Directors of the company will be held March 09, 2019, to consider the same

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.